The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
MYC Deregulation in Primary Human Cancers
Open accessAbstract
MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, MYC is a master regulator of many processes, including cell cycle entry, ribosome biogenesis, and metabolism. In cancer, the activity of the MYC transcriptional network is frequently deregulated, contributing to the initiation and maintenance of disease. Deregulation often leads to constitutive overexpression of MYC, which can be achieved through gross genetic abnormalities, including copy number alterations, chromosomal translocations, increased enhancer activity, or through aberrant signal transduction leading to increased MYC transcription or increased MYC mRNA and protein stability. Herein, we summarize the frequency and modes of MYC deregulation and describe both well-established and more recent findings in a variety of cancer types. Notably, these studies have highlighted that with an increased appreciation for the basic mechanisms deregulating MYC in cancer, new therapeutic vulnerabilities can be discovered and potentially exploited for the inhibition of this potent oncogene in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The RAF family of proteins (primarily BRAF) are also often mutated [160], with the most commonly observed mutations being valine-600 (V600), resulting in a constitutively activated kinase [183,184].”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 3×
“TCGA analysis (220 samples) and a larger meta-analysis (503 samples) identified the frequency of MYC amplification at 6% overall, while frequencies in the different subtypes ranged from 5% to 11% [39,40].”
BackgroundMethodLi, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Patients with metastatic castration-resistant prostate cancer (CRPC) treated androgen-directed therapies, including enzalutamide [50] and abiraterone acetate [51], eventually develop resistance characterized by low or absent androgen receptor (AR) expression and a neuroendocrine (CRPC-NE) phenotype.”
BackgroundThe landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
Super-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“This concept has already been highlighted by the discovery and use of the small molecule JQ1 as an inhibitor of MYC expression in malignancies where MYC expression is regulated by large enhancers, such as in MM [128,134].”
BackgroundIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“In a study of over 500 pancreatic ductal adenocarcinoma (PDAC) samples, MYC amplification was observed in 14% of PDAC and was enriched in the aggressive adenosquamous histological subtype [56,57].”
BackgroundA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015) · Współczesna Onkologia · doi:10.5114/wo.2014.47136 · Cited by 3,492
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.08.017 · Cited by 2,813
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715
Zhan, T., Rindtorff, N., & Boutros, M. (2017) · Oncogene · doi:10.1038/onc.2016.304 · Cited by 2,626
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
Kelly, K., Cochran, B. H., Stiles, C. D., & Leder, P. (1983) · Cell · doi:10.1016/0092-8674(83)90092-2 · Cited by 2,296
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“The RAS family of proteins are commonly mutated in many human cancers, with KRAS being the most commonly mutated family member [160,178].”
BackgroundPhosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Pan-cancer patterns of somatic copy number alteration
Zack, T. I., Schumacher, S. E., Carter, S. L., Cherniack, A. D., Saksena, G., Tabak, B., Lawrence, M. S., Zhang, C.-Z., Wala, J., Mermel, C. H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2760 · Cited by 1,870
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Ellisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,696
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Reflecting on 25 years with MYC
Meyer, N., & Penn, L. Z. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2231 · Cited by 1,575 · cited 1×
“Despite being essential for normal cellular proliferation [5,6], there is evidence that targeting MYC in cancer is a viable option [249].”
BackgroundSelf-citationTranscriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., & Leder, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7837 · Cited by 1,422
Schwab, M., Alitalo, K., Klempnauer, K.-H., Varmus, H. E., Bishop, J. M., Gilbert, F., Brodeur, G., Goldstein, M., & Trent, J. (1983) · Nature · doi:10.1038/305245a0 · Cited by 1,407
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Emerging landscape of oncogenic signatures across human cancers
Ciriello, G., Miller, M. L., Aksoy, B. A., Senbabaoglu, Y., Schultz, N., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,378
Genome-wide analysis of estrogen receptor binding sites
Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,377
Medulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S., Bouffet, E., Clifford, S. C., Hawkins, C. E., French, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,339
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
PI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,201
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
The lipid phosphatase activity of PTEN is critical for its tumor supressor function
Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · cited 2×
“In a study of over 500 pancreatic ductal adenocarcinoma (PDAC) samples, MYC amplification was observed in 14% of PDAC and was enriched in the aggressive adenosquamous histological subtype [56,57].”
BackgroundIntegrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer
Zhang, H., Liu, T., Zhang, Z., Payne, S. H., Zhang, B., McDermott, J. E., Zhou, J.-Y., Petyuk, V. A., Chen, L., Ray, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.069 · Cited by 1,029
Genomic targets of the human c-Myc protein
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A., & Amati, B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 973
Recurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960
Welcker, M., Orian, A., Jin, J., Grim, J. A., Harper, J. W., Eisenman, R. N., & Clurman, B. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402770101 · Cited by 941
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A. L., Hodson, D. J., Buras, E., et al. (2012) · Nature · doi:10.1038/nature11378 · Cited by 924
Amplification and expression of the c-myc oncogene in human lung cancer cell lines
Little, C. D., Nau, M. M., Carney, D. N., Gazdar, A. F., & Minna, J. D. (1983) · Nature · doi:10.1038/306194a0 · Cited by 920
Subgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Sorana Morrissy, A., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 899
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma
Weng, A. P., Millholland, J. M., Yashiro-Ohtani, Y., Arcangeli, M. L., Lau, A., Wai, C., del Bianco, C., Rodriguez, C. G., Sai, H., Tobias, J., et al. (2006) · Genes & Development · doi:10.1101/gad.1450406 · Cited by 870
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Turner, K. M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K., Ren, B., Nathanson, D. A., et al. (2017) · Nature · doi:10.1038/nature21356 · Cited by 847
Novel mutations target distinct subgroups of medulloblastoma
Robinson, G., Parker, M., Kranenburg, T. A., Lu, C., Chen, X., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 846
Dissecting the genomic complexity underlying medulloblastoma
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature · doi:10.1038/nature11284 · Cited by 839
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., Ishida, N., Okumura, F., Nakayama, K., & Nakayama, K. I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600217 · Cited by 808
Human Sos1: a Guanine Nucleotide Exchange Factor for Ras that Binds to GRB2
Chardin, P., Camonis, J. H., Gale, N. W., van Aelst, L., Schlessinger, J., Wigler, M. H., & Bar-Sagi, D. (1993) · Science · doi:10.1126/science.8493579 · Cited by 797
Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
Fishbein, L., Leshchiner, I., Walter, V., Danilova, L., Robertson, A. G., Johnson, A. R., Lichtenberg, T. M., Murray, B. A., Ghayee, H. K., Else, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.001 · Cited by 789
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature · doi:10.1038/nature11329 · Cited by 750
Bartram, C. R., de Klein, A., Hagemeijer, A., van Agthoven, T., van Kessel, A. G., Bootsma, D., Grosveld, G., Ferguson-Smith, M. A., Davies, T., Stone, M., et al. (1983) · Nature · doi:10.1038/306277a0 · Cited by 747
PVT1 dependence in cancer with MYC copy-number increase
Tseng, Y.-Y., Moriarity, B. S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H., Ronning, P., Reuland, B., Guenther, K., Beadnell, T. C., et al. (2014) · Nature · doi:10.1038/nature13311 · Cited by 722
Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity
Ayer, D. E., Kretzner, L., & Eisenman, R. N. (1993) · Cell · doi:10.1016/0092-8674(93)90661-9 · Cited by 703
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer
Nau, M. M., Brooks, B. J., Battey, J., Sausville, E., Gazdar, A. F., Kirsch, I. R., McBride, O. W., Bertness, V., Hollis, G. F., & Minna, J. D. (1985) · Nature · doi:10.1038/318069a0 · Cited by 665
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
Pomerantz, M. M., Ahmadiyeh, N., Jia, L., Herman, P., Verzi, M. P., Doddapaneni, H., Beckwith, C. A., Chan, J. A., Hills, A., Davis, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.403 · Cited by 663
Multiple regions within 8q24 independently affect risk for prostate cancer
Haiman, C. A., Patterson, N., Freedman, M. L., Myers, S. R., Pike, M. C., Waliszewska, A., Neubauer, J., Tandon, A., Schirmer, C., McDonald, G. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2015 · Cited by 663
O'Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J., Welcker, M., Meijerink, J. P., Pieters, R., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070876 · Cited by 663
Cloning of bovine GAP and its interaction with oncogenic ras p21
Vogel, U. S., Dixon, R. A. F., Schaber, M. D., Diehl, R. E., Marshall, M. S., Scolnick, E. M., Sigal, I. S., & Gibbs, J. B. (1988) · Nature · doi:10.1038/335090a0 · Cited by 649
Molyneux, E. M., Rochford, R., Griffin, B., Newton, R., Jackson, G., Menon, G., Harrison, C. J., Israels, T., & Bailey, S. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61177-x · Cited by 613
Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line
Collins, S., & Groudine, M. (1982) · Nature · doi:10.1038/298679a0 · Cited by 613
Genomic hallmarks of localized, non-indolent prostate cancer
Fraser, M., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 600
The genetic landscape of mutations in Burkitt lymphoma
Love, C., Sun, Z., Jima, D., Li, G., Zhang, J., Miles, R., Richards, K. L., Dunphy, C. H., Choi, W. W. L., Srivastava, G., et al. (2012) · Nature Genetics · doi:10.1038/ng.2468 · Cited by 597
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Peifer, M., Hertwig, F., Roels, F., Dreidax, D., Gartlgruber, M., Menon, R., Krämer, A., Roncaioli, J. L., Sand, F., Heuckmann, J. M., et al. (2015) · Nature · doi:10.1038/nature14980 · Cited by 595
The CORGI Consortium, Tomlinson, I. P., The EPICOLON Consortium, Webb, E., Carvajal-Carmona, L., Broderick, P., Howarth, K., Pittman, A. M., Spain, S., Lubbe, S., et al. (2008) · Nature Genetics · doi:10.1038/ng.111 · Cited by 562
Oncogenic activity of the c-Myc protein requires dimerization with Max
Amati, B., Brooks, M. W., Levy, N., Littlewood, T. D., Evan, G. I., & Land, H. (1993) · Cell · doi:10.1016/0092-8674(93)90663-b · Cited by 560
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma
Comino-Méndez, I., Gracia-Aznárez, F. J., Schiavi, F., Landa, I., Leandro-García, L. J., Letón, R., Honrado, E., Ramos-Medina, R., Caronia, D., Pita, G., et al. (2011) · Nature Genetics · doi:10.1038/ng.861 · Cited by 526
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Liu, W., Dong, X., Mai, M., Seelan, R. S., Taniguchi, K., Krishnadath, K. K., Halling, K. C., Cunningham, J. M., Qian, C., Christensen, E., et al. (2000) · Nature Genetics · doi:10.1038/79859 · Cited by 510
Cairo, S., Armengol, C., De Reyniès, A., Wei, Y., Thomas, E., Renard, C.-A., Goga, A., Balakrishnan, A., Semeraro, M., Gresh, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.002 · Cited by 509
FBXW7/hCDC4 Is a General Tumor Suppressor in Human Cancer
Akhoondi, S., Sun, D., von der Lehr, N., Apostolidou, S., Klotz, K., Maljukova, A., Cepeda, D., Fiegl, H., Dofou, D., Marth, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1320 · Cited by 506
Skp2 is oncogenic and overexpressed in human cancers
Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., & Krek, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081474898 · Cited by 505
Tuupanen, S., Turunen, M., Lehtonen, R., Hallikas, O., Vanharanta, S., Kivioja, T., Björklund, M., Wei, G., Yan, J., Niittymäki, I., et al. (2009) · Nature Genetics · doi:10.1038/ng.406 · Cited by 504
Nosaka, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4754 · Cited by 491
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V. B., Sharpe, H. J., McKee, T., Letourneau, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3525 · Cited by 490
TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b
Seoane, J., Pouponnot, C., Staller, P., Schader, M., Eilers, M., & Massagué, J. (2001) · Nature Cell Biology · doi:10.1038/35070086 · Cited by 489
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia
Thompson, B. J., Buonamici, S., Sulis, M. L., Palomero, T., Vilimas, T., Basso, G., Ferrando, A., & Aifantis, I. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070872 · Cited by 480
Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization
Gregory, M. A., Qi, Y., & Hann, S. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310722200 · Cited by 475
The ubiquitin-specific protease USP28 is required for MYC stability
Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., Elledge, S. J., & Eilers, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1601 · Cited by 474
Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
Shi, J., Whyte, W. A., Zepeda-Mendoza, C. J., Milazzo, J. P., Shen, C., Roe, J.-S., Minder, J. L., Mercan, F., Wang, E., Eckersley-Maslin, M. A., et al. (2013) · Genes & Development · doi:10.1101/gad.232710.113 · Cited by 463
Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max
Amati, B., Dalton, S., Brooks, M. W., Littlewood, T. D., Evan, G. I., & Land, H. (1992) · Nature · doi:10.1038/359423a0 · Cited by 460
Distinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants
Hemann, M. T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J. A., Cordon-Cardo, C., Cleveland, J. L., Tansey, W. P., & Lowe, S. W. (2005) · Nature · doi:10.1038/nature03845 · Cited by 452
Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.
Mateyak, M. K., Obaya, Á. J., Adachi, S., & Sedivy, J. M. (1997) · PubMed · Cited by 443
Skp2 Regulates Myc Protein Stability and Activity
Kim, S. Y., Herbst, A., Tworkowski, K. A., Salghetti, S. E., & Tansey, W. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00173-4 · Cited by 440
the ICGC MMML-Seq Project (2012) · Nature Genetics · doi:10.1038/ng.2469 · Cited by 440
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.
Escot, C., Theillet, C., Lidereau, R., Spyratos, F., Champeme, M. H., Gest, J., & Callahan, R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4834 · Cited by 412
Clonal selection drives genetic divergence of metastatic medulloblastoma
Wu, X., Northcott, P. A., Dubuc, A., Dupuy, A. J., Shih, D. J. H., Witt, H., Croul, S., Bouffet, E., Fults, D. W., Eberhart, C. G., et al. (2012) · Nature · doi:10.1038/nature10825 · Cited by 407
Herranz, D., Ambesi-Impiombato, A., Palomero, T., Schnell, S. A., Belver, L., Wendorff, A. A., Xu, L., Castillo-Martin, M., Llobet-Navás, D., Cordon-Cardo, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3665 · Cited by 405
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.62 · Cited by 389
Active medulloblastoma enhancers reveal subgroup-specific cellular origins
Lin, C. Y., Erkek, S., Tong, Y., Yin, L., Federation, A. J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.-J., et al. (2016) · Nature · doi:10.1038/nature16546 · Cited by 380
A common genetic risk factor for colorectal and prostate cancer
Haiman, C. A., Le Marchand, L., Yamamato, J., Stram, D. O., Sheng, X., Kolonel, L. N., Wu, A. H., Reich, D., & Henderson, B. E. (2007) · Nature Genetics · doi:10.1038/ng2098 · Cited by 365
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
Janoueix-Lerosey, I., Schleiermacher, G., Michels, E., Mosseri, V., Ribeiro, A., Lequin, D., Vermeulen, J., Couturier, J., Peuchmaur, M., Valent, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0630 · Cited by 349
Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers
Zhang, X., Choi, P. S., Francis, J. M., Imielinski, M., Watanabe, H., Cherniack, A. D., & Meyerson, M. (2016) · Nature Genetics · doi:10.1038/ng.3470 · Cited by 348
The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability
King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Aranda-Orgilles, B., Perez-Garcia, A., Shi, J., Vakoc, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.041 · Cited by 347
Ahmadiyeh, N., Pomerantz, M. M., Grisanzio, C., Herman, P., Jia, L., Almendro, V., He, H. H., Brown, M., Liu, X. S., Davis, M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910668107 · Cited by 336
Divergent clonal selection dominates medulloblastoma at recurrence
Morrissy, A. S., Garzia, L., Shih, D. J. H., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F. M. G., Ramaswamy, V., Lindsay, P. E., et al. (2016) · Nature · doi:10.1038/nature16478 · Cited by 334
The activation of phosphatidylinositol 3-kinase by Ras
Kodaki, T., Woscholski, R., Hallberg, B., Rodriguez-Viciana Julian Downward, P., & Parker, P. J. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00177-9 · Cited by 329
Chen, C.-R., Kang, Y., & Massagué, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.992 · Cited by 320
A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size
Welcker, M., Orian, A., Grim, J. A., Eisenman, R. N., & Clurman, B. E. (2004) · Current Biology · doi:10.1016/j.cub.2004.09.083 · Cited by 312
A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma
Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelstein, D., Qu, C., Pounds, S., Ellison, D. W., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.023 · Cited by 305
Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast.
Tanaka, T., Kimura, M., Matsunaga, K., Fukada, D., Mori, H., & Okano, Y. (1999) · PubMed · Cited by 301
Mechanism of estrogen activation of c-myc oncogene expression.
Dubik, D., & Shiu, R. P. C. (1992) · PubMed · Cited by 294
Kopan, R. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011213 · Cited by 294
Human small-cell lung cancers show amplification and expression of the N-myc gene.
Nau, M. M., Brooks, B. J., Carney, D. N., Gazdar, A. F., Battey, J. F., Sausville, E. A., & Minna, J. D. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.4.1092 · Cited by 293
Bahram, F., von der Lehr, N., Cetinkaya, C., & Larsson, L.-G. (2000) · Blood · doi:10.1182/blood.v95.6.2104 · Cited by 286
Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., & Magrath, I. (1993) · Nature Genetics · doi:10.1038/ng0993-56 · Cited by 285
Myc oncoproteins are phosphorylated by casein kinase II.
Lüscher, B., Kuenzel, E. A., Krebs, E. G., & Eisenman, R. N. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03481.x · Cited by 279
Dubik, D., Dembinski, T. C., & Shiu, R. P. C. (1987) · PubMed · Cited by 276
Chng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., Garbitt, V. M., Riggs, D. L., Brents, L. A., Roschke, A. V., et al. (2014) · Leukemia · doi:10.1038/leu.2014.70 · Cited by 268
Westermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K.-O., Oberthuer, A., Brors, B., Beissbarth, T., Vandesompele, J., Pattyn, F., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-10-r150 · Cited by 264
Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chenard, M., Long, B., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 264
Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter
Eberhardy, S. R., & Farnham, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207441200 · Cited by 262
Wright, J. B., Brown, S. J., & Cole, M. D. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01384-09 · Cited by 258
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia
Sanchez-Martin, M., & Ferrando, A. (2017) · Blood · doi:10.1182/blood-2016-09-692582 · Cited by 256
Zhu, J., Blenis, J., & Yuan, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802785105 · Cited by 246
Purification of ras GTPase activating protein from bovine brain.
Gibbs, J. B., Schaber, M. D., Allard, W. J., Sigal, I. S., & Scolnick, E. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5026 · Cited by 245
Negative autoregulation of c-myc transcription.
Penn, L. J., Brooks, M. W., Laufer, E. M., & Land, H. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08217.x · Cited by 244
Self-citationc-myc Is a Downstream Target of the Smad Pathway
Yagi, K., Furuhashi, M., Aoki, H., Goto, D., Kuwano, H., Sugamura, K., Miyazono, K., & Kato, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104170200 · Cited by 244
Genome-wide association studies in cancer
Easton, D. F., & Eeles, R. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn287 · Cited by 243
Enhancer variants: evaluating functions in common disease
Corradin, O., & Scacheri, P. C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0085-3 · Cited by 241 · cited 1×
“This includes enhancer regions, and in some cases SNPs have been implicated in altering enhancer activity [113,114].”
BackgroundMarcu, K. B., Harris, L. J., Stanton, L. W., Erikson, J., Watt, R., & Croce, C. M. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.2.519 · Cited by 232
Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo.
Pulverer, B., Fisher, C., Vousden, K. H., Littlewood, T. D., Evan, G. I., & Woodgett, J. R. (1994) · PubMed · Cited by 228
Lord, J. D., McIntosh, B. C., Greenberg, P. D., & Nelson, B. H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2533 · Cited by 227
The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc
Sun, X.-X., He, X., Yin, L., Komada, M., Sears, R. C., & Dai, M.-S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411713112 · Cited by 221
Frederick, J. P., Liberati, N. T., Waddell, D. S., Shi, Y., & Wang, X.-F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.6.2546-2559.2004 · Cited by 221
Lutterbach, B., & Hann, S. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5510 · Cited by 220
Kim, J., Lee, J.-H., & Iyer, V. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001798 · Cited by 218
Faiola, F., Liu, X., Lo, S., Pan, S., Zhang, K., Lymar, E., Farina, A., & Martinez, E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10220-10234.2005 · Cited by 218
Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC
Swartling, F. J., Savov, V., Persson, A. I., Chen, J., Hackett, C. S., Northcott, P. A., Grimmer, M. R., Lau, J., Chesler, L., Perry, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.012 · Cited by 215
c-Myc Mediates Activation of the cad Promoter via a Post-RNA Polymerase II Recruitment Mechanism
Eberhardy, S. R., & Farnham, P. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m109014200 · Cited by 215
Hill, R. M., Kuijper, S., Lindsey, J. C., Petrie, K., Schwalbe, E. C., Barker, K., Boult, J. K. R., Williamson, D., Ahmad, Z., Hallsworth, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.002 · Cited by 210
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Heyn, H., Vidal, E., Ferreira, H. J., Vizoso, M., Sayols, S., Gomez, A., Moran, S., Boque-Sastre, R., Guil, S., Martinez-Cardus, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0879-2 · Cited by 208
Etiology-dependent molecular mechanisms in human hepatocarcinogenesis
Schlaeger, C., Longerich, T., Schiller, C., Bewerunge, P., Mehrabi, A., Toedt, G., Kleeff, J., Ehemann, V., Eils, R., Lichter, P., et al. (2008) · Hepatology · doi:10.1002/hep.22033 · Cited by 203
Wasserman, N. F., Aneas, I., & Nobrega, M. A. (2010) · Genome Research · doi:10.1101/gr.105361.110 · Cited by 198
Zheng, F., Yue, C., Li, G., He, B., Cheng, W., Wang, X., Yan, M., Long, Z., Qiu, W., Yuan, Z., et al. (2016) · Nature Communications · doi:10.1038/ncomms10180 · Cited by 197
Mao, D. Y. L., Watson, J. D., Yan, P. S., Barsyte-Lovejoy, D., Khosravi, F., Wong, W. W.-L., Farnham, P. J., Huang, T. H.-M., & Penn, L. Z. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00297-5 · Cited by 185
Self-citationWnt signaling and colon carcinogenesis: Beyond APC
Najdi, R., Holcombe, R., & Waterman, M. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.78111 · Cited by 184
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.-U., Superti-Furga, G., & Sexl, V. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.775 · Cited by 183
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors
Richards, M. W., Burgess, S. G., Poon, E., Carstensen, A., Eilers, M., Chesler, L., & Bayliss, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610626113 · Cited by 180
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia
Radtke, I., Mullighan, C. G., Ishii, M., Su, X., Cheng, J., Ma, J., Ganti, R., Cai, Z., Goorha, S., Pounds, S. B., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903142106 · Cited by 177
Sutherland, K. D., & Berns, A. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.05.002 · Cited by 176
USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer
Pan, J., Deng, Q., Jiang, C., Wang, X., Niu, T., Li, H., Chen, T., Jin, J., Pan, W., Cai, X., et al. (2015) · Oncogene · doi:10.1038/onc.2014.327 · Cited by 169
Chandriani, S. J., Frengen, E., Cowling, V. H., Pendergrass, S. A., Perou, C. M., Whitfield, M. L., & Cole, M. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006693 · Cited by 168
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 167
Mitsiades, C. S., Mitsiades, N., Munshi, N. C., & Anderson, K. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.020 · Cited by 166
Romero, O. A., Torres-Diz, M., Pros, E., Savola, S., Gomez, A., Moran, S., Saez, C., Iwakawa, R., Villanueva, A., Montuenga, L. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0799 · Cited by 165
Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential.
Henriksson, M., Bakardjiev, A. I., Klein, G., & Lüscher, B. (1993) · PubMed · Cited by 162
Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer
Rennoll, S. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.290 · Cited by 162
Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tatò, F., & Nasi, S. (2002) · PubMed · Cited by 160
Kim, D., Hong, A., Park, H. I., Shin, W. H., Yoo, L., Jeon, S. J., & Chung, K. C. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25841 · Cited by 158
AXIN1 and AXIN2 variants in gastrointestinal cancers
Mazzoni, S. M., & Fearon, E. R. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.018 · Cited by 157
The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer
Diefenbacher, M. E., Popov, N., Blake, S. M., Schülein‐Völk, C., Nye, E. L., Spencer‐Dene, B., Jaenicke, L. A., Eilers, M., & Behrens, A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73733 · Cited by 156
Cowling, V. H., & Cole, M. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01828-06 · Cited by 155
The c-Myc Transactivation Domain Is a Direct Modulator of Apoptotic versus Proliferative Signals
Chang, D. W.-W., Claassen, G. F., Hann, S., & Cole, M. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.12.4309-4319.2000 · Cited by 154
DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
Stone, A. M., Zotenko, E., Locke, W. J., Korbie, D. J., Millar, E. K. A., Pidsley, R., Stirzaker, C., Graham, P., Trau, M., Musgrove, E. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms8758 · Cited by 150
Chromosome 14 translocation in african and north american burkitt's lymphoma
Hecht, B. K., Epstein, A. L., Kaplan, H. S., & Hecht, F. (1977) · International Journal of Cancer · doi:10.1002/ijc.2910190408 · Cited by 150
Reversible Smad-Dependent Signaling between Tumor Suppression and Oncogenesis
Sekimoto, G., Matsuzaki, K., Yoshida, K., Mori, S., Murata, M., Seki, T., Matsui, H., Fujisawa, J., & Okazaki, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4629 · Cited by 146
Calonge, M. J., & Massagué, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33637 · Cited by 144
Activation of Phosphoinositide 3-Kinase γ by Ras
Suire, S., Hawkins, P. T., & Stephens, L. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00933-8 · Cited by 143
Aretz, S., Koch, A., Uhlhaas, S., Friedl, W., Propping, P., von Schweinitz, D., & Pietsch, T. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20698 · Cited by 140
Chromosome 8q24-Associated Cancers and MYC
Grisanzio, C., & Freedman, M. L. (2010) · Genes & Cancer · doi:10.1177/1947601910381380 · Cited by 132
Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling
Stewart, A. K., & Fonseca, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.023 · Cited by 131
Characterization of MYC Translocations in Multiple Myeloma Cell Lines
Dib, A., Gabrea, A., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn011 · Cited by 131
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
MYC as a target for cancer treatment
Duffy, M. J., O'Grady, S., Tang, M., & Crown, J. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102154 · Cited by 514
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 397
Polyamines in cancer: integrating organismal metabolism and antitumour immunity
Holbert, C. E., Cullen, M. T., Casero, R. A., & Stewart, T. M. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00473-2 · Cited by 350
Metadata
- Authors
- Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2017-05-25
- Volume
- 8
- Issue
- 6
- Pages
- 151
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2618573553
- Cited by
- 443
- References
- 249
- FWCI
- 14.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.